Recurrent Clinical Trial
Official title:
Phase 2 Study of an Immune Therapy, DPX-Survivac With Low Dose Cyclophosphamide Administered With Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphamide (50 mg BID) for one year or until disease progression, whichever occurs first. Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.
This is a Phase 2, non-randomized, open-label, uncontrolled, efficacy and safety trial. Participants will receive 2 priming injections (0.5ml) of DPX-Survivac 3 weeks apart on Study Days 7 and 28. In addition, up to 6 maintenance injections (0.1ml) over the course of the study occurring on Study Days 84, 140, 196, 252, 308, and 364. All injections will be given under the skin of the upper thigh. Participants will receive metronomic oral cyclophosphamide (50mg BID; 7 days on / 7 days off) for study period. Pembrolizumab 200mg will be administered intravenously every 3 weeks, commencing on study day 7, to a total of 18 infusions. If a participant is removed from the trial prior to the completion of at least 4 doses of Pembrolizumab and 3 injections of DPX-Survivac, that particiapnt may be replaced to determine the efficacy of treatment in a minimum of 16 participants. DPX-Survivac injection sites will be evaluated throughout the study and if evidence of significant reaction, an Injection site reaction biopsy will be sought. During the course of the study, blood will be drawn to evaluate immune cells and the effect that DPX Survivac will have on the participants immune system. During all treatment cycles a physical exam and questions about the participants general health will be performed. Participants will undergo "re-staging" to assess the status of their disease at approximately study day 70 (if there is evidence of Grade 2 or greater injection site reaction or ulceration evident on study day 49) or routinely at approximately study day 91, and again at end of study or study withdrawal for all participants. A follow-up tumour biopsy will be requested between study day 77-83 for participants with any grade 2 or greater Injection site reaction or ulceration on SD49 or between SD98 and SD104 if no evidence of injection site reaction or ulceration. Upon completion of study, participants will be monitored every 2 months for 1 year. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05807984 -
Re-irradiation Therapy of Locally Recurrent Rectal Cancer With Carbon Ion
|
Phase 2 | |
Recruiting |
NCT05772390 -
Partial Breast Re-irradiation in Women in Women With Locally Recurrent Breast Cancer Previously Treated With Conservative Surgery and Whole Breast Irradiation
|
Phase 2 | |
Active, not recruiting |
NCT02069730 -
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
|
N/A | |
Recruiting |
NCT06164600 -
Bovine Colostrum for Prophylaxis Against Recurrent Urinary Tract Infection in Children
|
Phase 2 | |
Not yet recruiting |
NCT06305299 -
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
|
Phase 1 | |
Completed |
NCT01145872 -
The Effects and Mechanisms of Mindfulness Based Cognitive Therapy (MBCT) on Depressive Symptoms and Depression Relapse
|
Phase 3 | |
Recruiting |
NCT00510107 -
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGC
|
Phase 2 | |
Active, not recruiting |
NCT01883297 -
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Recruiting |
NCT06314152 -
3-point With 1-point Mesh Fixation in TAPP for Inguinal Hernia
|
N/A | |
Recruiting |
NCT01151722 -
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage
|
Phase 2 | |
Not yet recruiting |
NCT04599452 -
NK Cell Therapy Recurrent/Refractory Elderly AML
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007937 -
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06096038 -
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
|
Phase 1/Phase 2 | |
Recruiting |
NCT00364962 -
Treatment Result of KTP Laser Nasopharyngectomy in Recurrent NPC Patients
|
N/A |